| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
26,020,000 |
| Market
Cap: |
227.68(M) |
| Last
Volume: |
6,675 |
Avg
Vol: |
6,625 |
| 52
Week Range: |
$3.99 - $9.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Home Health Care |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 6.8 |
| Insider 3/6 Months : 7.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK™ (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK™ as a chemoprotectant and is developing PEDMARK™ as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,965 |
15,000 |
56,667 |
| Total Buy Value |
$0 |
$97,615 |
$104,601 |
$104,601 |
| Total People Bought |
0 |
1 |
1 |
3 |
| Total Buy Transactions |
0 |
1 |
2 |
4 |
| Total Shares Sold |
98,889 |
130,008 |
208,110 |
645,273 |
| Total Sell Value |
$920,630 |
$1,175,176 |
$1,668,324 |
$5,406,401 |
| Total People Sold |
3 |
3 |
3 |
5 |
| Total Sell Transactions |
7 |
11 |
22 |
53 |
| End Date |
2025-08-17 |
2025-05-16 |
2024-11-15 |
2023-11-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Clark John Smith Ii |
10% Owner |
– – • |
2025-11-17 |
4 |
S |
$8.79 |
$755,193 |
I/I |
(85,918) |
3,764,082 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-11-14 |
4 |
S |
$8.00 |
$1,280,432 |
I/I |
(160,100) |
3,850,000 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-11-05 |
4 |
AS |
$8.10 |
$81,000 |
D/D |
(10,000) |
82,318 |
|
-5% |
|
| Raykov Rosty |
|
– • – |
2025-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
92,318 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,430 |
173,104 |
|
- |
|
| Rallis Chris A |
|
– • – |
2025-10-10 |
4 |
AS |
$9.24 |
$16,401 |
D/D |
(1,775) |
57,079 |
|
-8% |
|
| Rallis Chris A |
|
– • – |
2025-10-10 |
4 |
OE |
$1.23 |
$4,996 |
D/D |
4,062 |
58,854 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-10-09 |
4 |
S |
$9.35 |
$192,614 |
I/I |
(20,609) |
4,010,100 |
|
16% |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-10-08 |
4 |
S |
$9.47 |
$185,722 |
I/I |
(19,605) |
4,030,709 |
|
15% |
|
| Raykov Rosty |
|
– • – |
2025-10-08 |
4 |
OE |
$2.45 |
$11,292 |
D/D |
4,609 |
87,110 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-10-07 |
4 |
S |
$9.59 |
$257,893 |
I/I |
(26,900) |
4,050,314 |
|
17% |
|
| Raykov Rosty |
|
– • – |
2025-10-06 |
4 |
AS |
$9.78 |
$97,800 |
D/D |
(10,000) |
82,501 |
|
-19% |
|
| Raykov Rosty |
|
– • – |
2025-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
92,501 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,430 |
170,674 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-09-05 |
4 |
OE |
$2.45 |
$88,707 |
D/D |
36,207 |
87,293 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-09-04 |
4 |
AS |
$8.92 |
$89,200 |
D/D |
(10,000) |
51,086 |
|
-14% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
168,244 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
61,086 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-08-05 |
4 |
AS |
$8.09 |
$80,900 |
D/D |
(10,000) |
55,878 |
|
-4% |
|
| Raykov Rosty |
|
– • – |
2025-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
65,878 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
165,813 |
|
- |
|
| Rallis Chris A |
|
– • – |
2025-07-07 |
4 |
AS |
$8.71 |
$9,746 |
D/D |
(1,119) |
54,792 |
|
-6% |
|
| Rallis Chris A |
|
– • – |
2025-07-07 |
4 |
OE |
$2.35 |
$4,998 |
D/D |
2,127 |
55,911 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-07-03 |
4 |
AS |
$8.61 |
$86,100 |
D/D |
(10,000) |
60,670 |
|
-13% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
163,382 |
|
- |
|
298 Records found
|
|
Page 1 of 12 |
|
|
0.89 (11.32%) 
